Glenmark’s innovative nasal spray gets EU marketing approval

INDIA – Glenmark Pharmaceuticals has announced that its fixed-dose combination nasal spray, Ryaltris, has received marketing approval in 13 countries across the EU and the UK, bolstering the company’s respiratory therapy line. Glenmark is a global research-led pharmaceutical company with operations in over 50 countries and a presence in generics, specialty, and over-the-counter (OTC) businesses. Glenmark’s primary therapeutic focus areas include respiratory, dermatology, and oncology. In terms of revenue, it is ranked among the top 80 Pharma & Biotech companies in the world. Ryaltris is a combination of antihistamine plus…

Read More